NGL Fine-Chem Limited (NSE:NGLFINE)
2,871.90
-62.90 (-2.14%)
Nov 11, 2026, 1:53 PM IST
NGL Fine-Chem Revenue
NGL Fine-Chem had revenue of 1.60B INR in the quarter ending September 30, 2026, with 32.97% growth. This brings the company's total for the last twelve months to 5.75B, up 40.67% year-over-year. In the fiscal year ending March 31, 2026, NGL Fine-Chem had annual revenue of 5.01B with 36.03% growth.
Revenue (ttm)
5.75B
Revenue Growth
+40.67%
P/S Ratio
3.15
Revenue / Employee
11.54M
Employees
498
Market Cap
17.73B
Revenue by Geography
- Rest of The World 1.91B 38.6%
- India 1.58B 32.0%
- Asia Pacific 1.44B 29.2%
- Europe 6.87M 0.1%
- USA 1.50M 0.0%
Fiscal year ended Mar 31, 2026 See the full NGL Fine-Chem breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 5.01B | 1.33B | 36.03% |
| Mar 31, 2025 | 3.68B | 295.68M | 8.73% |
| Mar 31, 2024 | 3.39B | 606.08M | 21.79% |
| Mar 31, 2023 | 2.78B | -394.22M | -12.42% |
| Mar 31, 2022 | 3.18B | 595.28M | 23.08% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Marksans Pharma | 33.92B |
| Pfizer | 26.54B |
| Rubicon Research | 21.00B |
| CORONA Remedies | 15.59B |
| Sanofi Consumer Healthcare India | 9.79B |
| SMS Pharmaceuticals | 9.74B |
| Senores Pharmaceuticals | 7.19B |
| Sai Parenteral's | 6.74B |